Kalaris Therapeutics, Inc. (KLRS)
8.45
-0.22
(-2.54%)
USD |
NASDAQ |
Mar 16, 12:36
Kalaris Therapeutics EPS Diluted (Quarterly) : -0.636 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.596 |
| Agenus, Inc. | 1.944 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
| Savara, Inc. | -0.1341 |
| Arrowhead Pharmaceuticals, Inc. | 0.219 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.89M |
| Total Expenses (Quarterly) | 11.89M |
| Enterprise Value | 86.70M |
| Earnings Yield | -87.54% |
| Normalized Earnings Yield | -90.21 |